Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    32.665,21
    -944,64 (-2,81%)
     

  • Dow Jones

    38.589,16
    -57,94 (-0,15%)
     

  • Nasdaq

    17.688,88
    +21,32 (+0,12%)
     

  • Nikkei 225

    38.814,56
    +94,09 (+0,24%)
     

  • Petrolio

    78,49
    -0,13 (-0,17%)
     

  • Bitcoin EUR

    61.981,71
    +174,49 (+0,28%)
     

  • CMC Crypto 200

    1.379,89
    -37,99 (-2,68%)
     

  • Oro

    2.348,40
    +30,40 (+1,31%)
     

  • EUR/USD

    1,0709
    -0,0033 (-0,31%)
     

  • S&P 500

    5.431,60
    -2,14 (-0,04%)
     

  • HANG SENG

    17.941,78
    -170,85 (-0,94%)
     

  • Euro Stoxx 50

    4.839,14
    -96,36 (-1,95%)
     

  • EUR/GBP

    0,8438
    +0,0026 (+0,31%)
     

  • EUR/CHF

    0,9526
    -0,0069 (-0,72%)
     

  • EUR/CAD

    1,4693
    -0,0057 (-0,39%)
     

BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting

BeyondSpring, Inc.
·1 minuto per la lettura
BeyondSpring, Inc.
BeyondSpring, Inc.

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced the presentation of a poster at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA.

The poster, titled, “​​Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with Immune Checkpoint Blockade,” will be presented by Dr. Steven H. Lin, MD., Ph.D., physician-scientist, radiation oncologist and professor who specializes in thoracic malignancies at The University of Texas MD Anderson Cancer Center.

Additional presentation details are as follows:

ANNUNCIO PUBBLICITARIO

  • Poster Session Date / Time: Saturday, November 4th, 2023, at 9 a.m. to 8:30 p.m. PDT

  • Location: San Diego Convention Center, Exhibit Halls A and B1

  • Type of Presentation: Poster Presentation

  • Abstract No.: 732

About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com, and follow us on LinkedIn and Twitter.

Investor Contact:
IR@beyondspringpharma.com

Media Contact:
PR@beyondspringpharma.com